 Although there is currently no standard chemotherapy for patients with advanced biliary tract cancers ABC the UK ABC-02 study the largest study by far in this patient group, n410 is likely to define CisGem as the global standard of care for this disease based on a significantly improved progression-free survival and overall survival compared to gemcitabine alone. 